Teva Pharmaceutical Industries Limited Posted losses of -2.08% in the Last Trade


Teva Pharmaceutical Industries Limited (TEVA) belongs to the “Healthcare” sector with an industry focus on “Drug Manufacturers – Other”, with Dr. Carlo  De Notaristefani Ph.D. as Chief Exec. Officer of Global Operations and Pres of Global Operations.

The company has been one of the biggest innovators in “Drug Manufacturers – Other” employing approximately 56960 full time employees.

Key Statistics:

  • The stock subtracted in the prior trading session by -2.08%, closing at the stock price of $29.67.
  • Currently, the market capitalization of Teva Pharmaceutical Industries Limited (TEVA) is 30.27 Billion.
  • TEVA has a 1-year high price of $ 55.04 and 1-year low price of $30.20.
  • The number of shares currently held by investors is 1.02 Billion.
  • The number of shares traded in the last trading session was 12.77 Million.


The company reported an impressive total revenue of 21.9 Billion in the last fiscal year.

If you look at the company’s income statement over the past years, you will see that the company is constantly posting gross profit: In 2014, TEVA earned gross profit of 11.06 Billion, in 2015 11.36 Billion gross profit, while in 2016 Teva Pharmaceutical Industries Limited (TEVA) produced 11.86 Billion profit.

Currently the shares of Teva Pharmaceutical Industries Limited (TEVA) has a trading volume of 12.77 Million shares, with an average trading volume of 9700 shares – with shares dropping to a 52 week low of $30.20, and the company’s shares hitting a 52 week high of $ 55.04.

Looking at the current price of the stock and the 52 week high and low, it suggests that the stock is likely to go Up in the future.

Earnings per share (EPS) breaks down the profitability of the company on a single share basis, and for Teva Pharmaceutical Industries Limited the EPS stands at 1.06 for the previous quarter, while the analysts predicted the EPS of the stock to be 1.03, suggesting the stock exceeded the analysts’ expectations.

Another critical number in evaluating a stock is P/E or the price to earnings ratio.

Currently the P/E of Teva Pharmaceutical Industries Limited stands at 191.42. Looking at this figure it suggests that the shares of Teva Pharmaceutical Industries Limited (TEVA) may be overvalued, however, this can also depend upon the situation of the market; if the market is strong then it could suggest that Teva Pharmaceutical Industries Limited (TEVA) is a good investment, however if the market is weaker then it could suggest that the shares are undervalued.

The TTM operating margin is 0%. The return on invested capital at 1.1%, which is good, compared to its peers.

The Free Cash Flow or FCF margin is 0%, which means that the business has healthy reserve funds for contingencies that may arise.

Stock is currently moving with a negative distance from the 200 day simple moving average of approximately -23.6%, and has a poor year to date (YTD) performance of -17.37% which means the stock is constantly subtracting to its value from the previous fiscal year end price.

The stock diminished about -0.78% in the past 5 years, this negative value indicates that the stock constantly going down in previous years as well.

Future Expectations:

The target price for Teva Pharmaceutical Industries Limited (TEVA) is $37.75/share according to the consensus of analysts working on the stock, with an expected EPS of $1.14/share for the current quarter.

The company’s expected revenue in the current quarter to be 5.77 Billion, seeing a projected current quarter growth of -8.8%, and per annum growth estimates over the next 5 year period of around 2.83%.